I am a professor for a radiologic technology program and so I enjoy seeing things that mesh the field of radiology (specifically vascular/interventional stuff since I worked as a cardiovascular RT when I was working in the clinical setting) and diabetes.
Earlier this year, Medtronic received FDA approval for a new DES (drug eluting stent) that is specifically marketed with a first-of-its-kind clinical indication for patients with CAD (coronary artery disease) and diabetes.
It is interesting/noteworthy because the 2 year target lesion failure rate is relatively low (par with other DES, but specifically an improvement in individuals who also have diabetes compared to some others on the market right now). A study is still ongoing to track patient outcomes for future success.
You can read more of the story here...